Scribe Therapeutics secures $25m to advance CRISPR therapies (opens in new tab)

Scribe Therapeutics has been awarded more than $25 million by the California Institute for Regenerative Medicine to advance two preclinical CRISPR-based gene editing programs, STX-1200 and STX-1400, toward clinical trials. STX-1200 targets LPA to lower lipoprotein(a) in patients with genetically elevated Lp(a), and STX-1400 targets apoc3 to durably reduce triglyceride-rich lipoproteins and address acute pancreatitis […] The post appeared first on <a href="